Sherry Ann Fisher, 56, of Evansville, passed away Wednesday, May 28, 2025 at Deaconess Gateway Hospital in Evansville. She was born November 22, ...

Please provide your email address to receive an email when new articles are posted on . An AACE consensus statement outlines treatment recommendations for MEN1-associated tumors and genetic ...

A phase 1 trial combines immunotherapy and an oncolytic virus for high-grade neuroendocrine tumors, aiming to enroll 36 patients by 2030. The trial evaluates Opdivo, Yervoy, and Seneca Valley ...

Dr. Aman Chauhan, leader of the Neuroendocrine Tumor Program at Sylvester Comprehensive Cancer Center, is leading a clinical trial testing a combination of immunotherapy drugs and a tumor-busting ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

177Lu-edotreotide shows potential to extend progression-free survival in patients with grade 1 or 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

Automated radiomics model for preoperative pancreatic neuroendocrine tumor grade prediction.. If you have the appropriate software installed, you can download article citation data to the citation ...

Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients with gastroenteropancreatic neuroendocrine tumors, a phase 3 trial found.

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

"While lanreotide and everolimus have each previously demonstrated the ability to extend progression-free survival in patients with gastroenteropancreatic neuroendocrine tumors, combination ...

Gastro Esophageal Junction Neuroendocrine Tumor Market Outlook 2025-2035: The gastro esophageal junction neuroendocrine tumor market size reached a value of USD 1,120.2 Million in 2024. Looking ...